Economic evaluation of a hypothetical screening assay for alloimmunization risk among transfused patients with sickle cell disease

Transfusion

Volumn 54, Issue 8, 2014, Pages 2034-2044

  Kacker, Seema ^a   Ness, Paul M ^a   Savage, William J ^b   Frick, Kevin D ^c   Shirey, R Sue ^a   King, Karen E ^a   Tobian, Aaron A R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD GROUP ANTIGEN; BLOOD GROUP C ANTIGEN; BLOOD GROUP E ANTIGEN; K ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ALLOIMMUNIZATION; ARTICLE; BLOOD GROUP TYPING; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CHILD; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; HYPOTHETICAL SCREENING TEST; IMMUNOPROPHYLAXIS; MALE; MASS SCREENING; PATIENT RISK; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SICKLE CELL ANEMIA; TRANSFUSION MEDICINE;

ANEMIA, SICKLE CELL; BLOOD DONORS; BLOOD GROUP ANTIGENS; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUPING AND CROSSMATCHING; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; DONOR SELECTION; HEALTH EXPENDITURES; HUMANS; ISOANTIBODIES; MARKOV CHAINS; MEDICAL RECORDS; MODELS, ECONOMIC; RISK; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84906222827     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12585     Document Type: Article

References (36)

1. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F,. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012; 120: 528-537.
2. Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322: 1617-1621.
3. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990; 76: 1431-1437.
4. Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011; 51: 1732-1739.
5. Vichinsky EP,. The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells. Immunohematology 2012; 28: 20-23.
6. Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41: 1086-1092.
7. Sakhalkar VS, Roberts K, Hawthorne LM, et al. Allosensitization in patients receiving multiple blood transfusions. Ann N Y Acad Sci 2005; 1054: 495-499.
8. Aygun B, Padmanabhan S, Paley C, et al. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42: 37-43.
9. Karafin MS, Shirey RS, Ness PM, et al. Antigen-matched red blood cell transfusions for patients with sickle cell disease at The Johns Hopkins Hospital. Immunohematology 2012; 28: 3-6.
10. King KE, Shirey RS,. Transfusion management of patients with sickle cell disease: the continuing dilemma. Transfusion 2010; 50: 2-4.
11. Osby M, Shulman IA,. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med 2005; 129: 190-193.
12. Higgins JM, Sloan SR,. Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood 2008; 112: 2546-2553.
13. National Heart, Lung, and Blood Institute. Expert panel report on the management of sickle cell disease is available for public comment until August 31. 2012. Office of the Director. [cited 2013 Mar 18]. Available from: http://www.nhlbi.nih.gov/about/directorscorner/messages/2012-messages/ august-2012/expert-panel-report-on-the-management-of-sickle-cell-disease-is- available-for-public-comment-until-august-31/index.html
14. Kacker S, Ness PM, Savage WJ, et al. Cost-effectiveness of prospective red cell antigen-matching to prevent alloimmunization among sickle cell patients. Transfusion 2014; 54: 86-97.
15. Kacker S, Frick KD, Tobian AA,. The costs of transfusion: economic evaluations in transfusion medicine, part 1. Transfusion 2013; 53: 1383-1385.
16. Kacker S, Frick KD, Tobian AA,. Establishing a framework: economic evaluations in transfusion medicine, part 2. Transfusion 2013; 53: 1634-1636.
17. Kacker S, Frick KD, Tobian AA,. Constructing a model: economic evaluations in transfusion medicine, part 3. Transfusion 2013; 53: 1885-1887.
18. Kacker S, Frick KD, Tobian AA,. Data and interpretation: economic evaluations in transfusion medicine, part 4. Transfusion 2013; 53: 2130-2133.
19. Briggs A, Sculpher M,. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409.
20. United States Census. The 2012 statistical abstract: the national data book. Resident population by sex and age. 2013 [cited 2013 Apr 18]. Available from: http://www.census.gov/compendia/statab/cats/population.html
21. Fasano RM, Paul W, Siegal E, et al. Transfusion protocol for patients with sickle hemoglobinopathies at Children's National Medical Center. Immunohematology 2012; 28: 13-16.
22. AABB. 2013 Proposed Medicare payments for hospital outpatient services. 2012. [cited 23 Mar 18]. Available from: http://www.aabb.org/programs/ reimbursementinitiatives/Pages/13hoppsruleprop.aspx
23. Winkler AM, Josephson CD,. Transfusion practices for patients with sickle cell disease at major academic medical centers participating in the Atlanta Sickle Cell Consortium. Immunohematology 2012; 28: 24-26.
24. Centers for Medicare & Medicaid Services. Hospital outpatient prospective payment system: addendum A update. 2012. [cited 2013 Mar 18]. Available from: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates-Items/ 2012-July-Addendum-A.html
25. Moore RD, Charache S, Terrin ML, et al. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am J Hematol 2000; 64: 26-31.
26. Ambruso DR, Githens JH, Alcorn R, et al. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987; 27: 94-98.
27. Reid ME, Lomas-Francis C,. The blood group antigen factsbook. 2nd ed. Amsterdam; Boston (MA): Elsevier/Academic Press; 2004.
28. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253-1258.
29. Seielstad M, Page G, Gaddis N, et al. Genome-wide association study of HLA allo-antibody formation and persistence. AABB Meeting 2013 Abstract S88-040B. Transfusion 2013; 53 (Suppl): 53A.
30. Lee SC, Machado R, Ellis NA, et al. Percentage of West-African ancestry predicts red cell alloimmunization in transfused African American sickle cell disease (SCD) patients. AABB Meeting Abstract SP247. Transfusion 2013; 53 (Suppl): 153A.
31. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995; 333: 206-213.
32. Wahl SK, Garcia A, Hagar W, et al. Lower alloimmunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions. Transfusion 2012; 52: 2671-2676.
33. Venkateswaran L, Teruya J, Bustillos C, et al. Red cell exchange does not appear to increase the rate of allo- and auto-immunization in chronically transfused children with sickle cell disease. Pediatr Blood Cancer 2011; 57: 294-296.
34. Custer B,. Economic analyses of blood safety and transfusion medicine interventions: a systematic review. Transfus Med Rev 2004; 18: 127-143.
35. AuBuchon JP, Birkmeyer JD, Busch MP,. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 1997; 37: 45-51.
36. Jackson BR, Busch MP, Stramer SL, et al. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43: 721-729.